Compare Abeona Therapeutics Inc (ABEO) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs T-Mobile Us Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while T-Mobile Us Inc trades at $181.34 (market cap $199.92B). The key difference: T-Mobile Us Inc is far larger — about 535.5× Abeona Therapeutics Inc's market cap, and T-Mobile Us Inc pays a 2.21% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TMUS | |
|---|---|---|
Market Cap | $373.32M | $199.92B |
Sector | Health | Media |
52-Week High | $7.23 | $259.01 |
52-Week Low | $4.17 | $167.65 |
Enterprise Value | $228.22M | $317.61B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
T-Mobile US (TMUS) trades at $184.73, up 4.06% on the day, with a bullish analyst consensus but bearish technical signals. The stock shows strong fundamentals with revenue growth to $88.31B in 2025 and a net income margin of 11.65%, though earnings have been mixed with a recent miss in Q4 2025. Recent news includes leadership changes and speculation about SpaceX's potential interest, while cash flow remains positive but projected to decline in 2026.
Outlook: TMUS offers growth potential with solid profitability and analyst targets near $256, but faces risks from competitive pressures and debt levels. Investment appeal hinges on execution amid sector volatility and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
